Mei-Dan Elad, Walfisch Asnat, Martinowitz Uri, Hallak Mordechai
From the Department of Obstetrics & Gynecology, Hillel Yaffe Medical Center, Hadera, Israel; and Israel National Hemophilia Center, Sheba Medical Center, Tel-Hashomer, Israel.
Obstet Gynecol. 2009 Aug;114(2 Pt 2):417-419. doi: 10.1097/AOG.0b013e3181a602c4.
Postpartum hemorrhage may be a life-threatening event and may result from coagulation defects.
We report a case of a multigravida woman who developed rapidly progressive postpartum bleeding as a result of acquired factor VIII inhibitors. Repeated laparotomies and massive transfusions failed to achieve adequate control of bleeding. Laboratory studies revealed a prolonged activated partial thromboplastin time, and the presence of specific inhibitors was soon established. The patient responded only partially to steroids and immunotherapy. Upon administration of rituximab, an anti-CD-20 monoclonal antibody, control of bleeding was achieved.
Early diagnosis of acquired hemophilia as a rare cause of postpartum hemorrhage is crucial, because specific therapy may be life saving.